secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001808665-24-000041
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio Q3 net sales $28.7M, adj EBITDA $5.3M; board adds Stark, loses Staple/Vacirca
--------------------------------------------------------------------------------

- Q3 net product sales $28.7M vs $35.1M YoY; net loss $2.9M vs $279.5M loss (prior year impairment).
- Rolvedon net sales $15.0M (stable vs $15.1M Q2); Indocin $5.7M (down from $6.9M Q2) on generic competition.
- Adjusted EBITDA $5.3M (down from $12.9M YoY); adjusted EPS $0.03 vs $0.01 YoY.
- Cash and short-term investments $88.6M; debt $40M (6.5% convertible notes, maturity 2027).
- Board changes: Staple/Vacirca departed Nov 7; Mason appointed Chair; Stark (ex-Teva CLO) named independent director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000180866524000041/0001808665-24-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000180866524000041/asrt-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001808665-24-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer